drugset / Trial / NCT00538096
A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
* Evaluate the safety and tolerability of multiple doses of MEDI-538 by continuous IV infusion for 4 or 8 weeks in adult patients with B-cell NHL not eligible for curative therapy. * Determine the maximum tolerated dose of MEDI-538 administered by continuous IV infusion.
Timeline
- Start
- 2007-09
- Primary completion
- 2010-03
- Completion
- 2010-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Blinatumomab | Monoclonal antibody | 5 ug/m2 | Intravenous |
| Subject | Blinatumomab | Monoclonal antibody | 10 ug/m2 | Intravenous |
| Subject | Blinatumomab | Monoclonal antibody | 15 ug/m2 | Intravenous |